Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

09 Nov 2017

FTC Acting Chairman Ohlhausen predicts agency will continue to focus on competition issues involving barriers to generics but says 'we need to learn more about how these markets are working today.'

United States Federal Trade Commission building in Washington, DC

The US Federal Trade Commission wants to learn more about why generic competition does not always work the way it was intended by the Hatch-Waxman Act, Acting Chairman Maureen Ohlhausen commented during a public workshop on competition in prescription drug markets.

The Nov. 8 workshop served as a forum for discussing options for potential FTC enforcement action that would ultimately help...